J Clin Nephrol Kidney Dis | Volume 6, Issue 1 | Review Article | Open Access
Jessica Audet1, Jessica Pagé1, Suha Moten2* and Anis Rauf3
1Xavier University School of Medicine, Aruba
2Loyola University, Chicago IL, USA
3Nephrology Associates of Northern Illinois Hinsdale, USA
*Correspondance to: Suha MotenFulltext PDF
We conducted a thorough review of the effects of SGLT2 inhibitors on cardiorenal protection in diabetic and non-diabetic patients in randomized controlled trials and controlled observational studies. PubMed, NCBI database, uptodate.com and ClinicalTrials.gov were searched with date restriction until December 28th, 2020. The medical subject headings included the terms: “sodiumglucose transporter 2” in combination with “Heart failure”, “cardiovascular disease”, “CKD”, “renal failure” and “non-diabetic”. This retrospective search evaluated pertinent data and allowed for a thorough review of literature on the usage of SGLT-2 inhibitors in non-diabetic patients. The search was not limited to say study designs. JA and JP first independently screened titles and abstracts of all articles and reviewed full texts of the potentially relevant studies and cases for use in this article. SM wrote the review of literature alongside conducting a thorough evaluation on the current research available.
Audet J, Pagé J, Moten S, Rauf A. SGLT2 Inhibitors Use in Non-Diabetic Patients: A Narrative Review. J Clin Nephrol Kidney Dis. 2021;6(1):1029..